NewAmsterdam Pharma Co N.V.
- NAMS · Nasdaq
- Pharmaceutical Preparations
- Narrden, P7
- 100 employees
- CIK 0001936258
Updated from SEC filings through
Top things to know
Executives
-
Michael H. Davidson Chief Executive Officer Form 4, September 15, 2026 -
Ian Somaiya Chief Financial Officer 10-K, February 18, 2026 - Mayur Ian Somaiya Chief Financial Officer Form 4, January 22, 2026
- Robert William Gunning Vice President, Controller Form 4, September 3, 2026
- Johannes Jacob Pieter Kastelein Chief Scientific Officer Form 4, August 25, 2026
- Louise Frederika Kooij Chief Accounting Officer Form 4, July 22, 2026
NewAmsterdam Pharma Co N.V. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Narrden, P7. It trades as NAMS on Nasdaq. Revenue was $22.5M in the fiscal year ending December 31, 2025, -50.6% from the year before. It reported about 100 employees. Michael H. Davidson is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22.5M 10-K, 2026-02-18 | $45.6M 10-K, 2026-02-18 | $14.1M 10-K, 2026-02-18 | $103M 10-K, 2025-02-26 | Not on file |
| Operating income | -$226M 10-K, 2026-02-18 | -$176M 10-K, 2026-02-18 | -$183M 10-K, 2026-02-18 | -$3.6M 10-K, 2025-02-26 | -$35.0M 10-K, 2024-02-28 |
| SG&A | $106M 10-K, 2026-02-18 | $70.4M 10-K, 2026-02-18 | $37.6M 10-K, 2026-02-18 | $19.5M 10-K, 2025-02-26 | $6.0M 10-K, 2024-02-28 |
| Net income | -$204M 10-K, 2026-02-18 | -$242M 10-K, 2026-02-18 | -$177M 10-K, 2026-02-18 | -$22.6M 10-K, 2025-02-26 | -$41.8M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer | Form 4, September 15, 2026 |
| | Chief Financial Officer | 10-K, February 18, 2026 |
| Mayur Ian Somaiya | Chief Financial Officer | Form 4, January 22, 2026 |
| Robert William Gunning | Vice President, Controller | Form 4, September 3, 2026 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Form 4, August 25, 2026 |
| Louise Frederika Kooij | Chief Accounting Officer | Form 4, July 22, 2026 |
| | Chief Scientific Officer, Non-Executive Director | 10-K, February 18, 2026 |
| Mark C. McKenna | Vice Chair, Non-Executive Director | 10-K, February 18, 2026 |
| William H. Lewis, J.D., M.B.A. | Chair, Non-Executive Director | 10-K, February 18, 2026 |
| Adele Gulfo | Non-Executive Director | 10-K, February 18, 2026 |
| James N. Topper, M.D., Ph.D. | Non-Executive Director | 10-K, February 18, 2026 |
| Janneke van der Kamp | Non-Executive Director | 10-K, February 18, 2026 |
| John W. Smither | Non-Executive Director | 10-K, February 18, 2026 |
| Louis Lange, M.D., Ph.D. | Non-Executive Director | 10-K, February 18, 2026 |
| Wouter Joustra | Non-Executive Director | 10-K, February 18, 2026 |
What NewAmsterdam Pharma Co N.V. does
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 119.9 million (as of November 2, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $1.3B (as of June 30, 2025) | 10-K, February 18, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 6, 2026 (filed May 6, 2026) | DEF 14A, May 6, 2026 |
| Auditor | Deloitte Accountants B.V (Eindhoven, The Netherlands) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 30, 2026 | Johannes Jacob Pieter Kastelein Chief Scientific Officer | Sale | 50,246 | $1.3M | Form 4, October 2, 2026 |
| September 14, 2026 | Michael H. Davidson Chief Executive Officer | Buy | 10,000 | $227K | Form 4, September 15, 2026 |
| September 4, 2026 | John W. Smither Director | Sale | 1,600 | $41K | Form 4, September 9, 2026 |
| August 24, 2026 | Johannes Jacob Pieter Kastelein Chief Scientific Officer | Sale | 125,000 | $3.4M | Form 4, August 25, 2026 |
| July 20, 2026 | Louise Frederika Kooij Chief Accounting Officer | Sale | 105,000 | $3.2M | Form 4, July 22, 2026 |
| June 22, 2026 | Louise Frederika Kooij Chief Accounting Officer | Sale | 40,000 | $1.2M | Form 4, June 24, 2026 |
| May 26, 2026 | Louise Frederika Kooij Chief Accounting Officer | Sale | 65,000 | $2.3M | Form 4, May 27, 2026 |
| March 11, 2026 | Louis G. Lange Director | Sale | 44,619 | $1.4M | Form 4, March 12, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- 8-K filed 2026-09-29
- Item 8.01 Other events
- 8-K filed 2026-09-21
- Item 8.01 Other events
- 8-K filed 2026-08-14
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-24
- Item 8.01 Other events
- 8-K filed 2026-07-22
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-24
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about NewAmsterdam Pharma Co N.V.
- What does NewAmsterdam Pharma Co N.V. do?
- In its own words, from Item 1 of its 10-K: "We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy."
- What is NewAmsterdam Pharma Co N.V.'s revenue?
- $22.5M for the fiscal year ending December 31, 2025, from its 10-K filed February 18, 2026.
- Is NewAmsterdam Pharma Co N.V. profitable?
- NewAmsterdam Pharma Co N.V. reported net income of -$204M for the fiscal year ending December 31, 2025.
- How many employees does NewAmsterdam Pharma Co N.V. have?
- About 100 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of NewAmsterdam Pharma Co N.V.?
- Michael H. Davidson, Chief Executive Officer, as named in a 4 filed September 15, 2026.
- Who is the CFO of NewAmsterdam Pharma Co N.V.?
- Ian Somaiya, Chief Financial Officer, as named in a 10-K filed February 18, 2026.
- Where is NewAmsterdam Pharma Co N.V. headquartered?
- Narrden, P7.
- What is NewAmsterdam Pharma Co N.V.'s stock ticker?
- NAMS, NAMSW on Nasdaq.
- What industry is NewAmsterdam Pharma Co N.V. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is NewAmsterdam Pharma Co N.V.'s website?
- newamsterdampharma.com.
- When does NewAmsterdam Pharma Co N.V. report earnings next?
- January 8, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is NewAmsterdam Pharma Co N.V. a public company?
- Yes. NewAmsterdam Pharma Co N.V. files with the SEC under CIK 0001936258 and trades as NAMS.
- Who audits NewAmsterdam Pharma Co N.V.?
- Deloitte Accountants B.V, Eindhoven, The Netherlands, as named in its latest annual report (10-K).
- How many shares of NewAmsterdam Pharma Co N.V. are outstanding?
- 119.9 million shares as of November 2, 2026, from its 10-Q filed November 4, 2026.
- What is NewAmsterdam Pharma Co N.V.'s public float?
- $1.3B as of June 30, 2025, as reported on the cover of its 10-K filed February 18, 2026.
- How many business segments does NewAmsterdam Pharma Co N.V. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is NewAmsterdam Pharma Co N.V.'s annual shareholder meeting?
- May 6, 2026, per its proxy statement (DEF 14A) filed May 6, 2026.
- Have NewAmsterdam Pharma Co N.V. insiders traded stock recently?
- Since July 16, 2025, officers and directors reported 25 open-market sales worth about $72.4M and 4 purchases worth about $285K on Forms 4 and 5. The most recent: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 50,246 shares on September 30, 2026.